We Need More Breast Cancer Trials For Younger Patients Urge Experts
6/03/2013
The poorer survival rates of younger breast cancer patients could be a result of insufficient clinical trials for this age group. This was a conclusion of a major new Cancer Research UK study published online recently in the Journal of the National Cancer Institute (JNCI)...
New Anticancer Drug Shows Effect Against Melanoma
6/03/2013
A new drug being tested in patients with advanced melanoma, the most dangerous form of skin cancer, has shown significant antitumor activity, according to preliminary results of a new study. The research, conducted by a team of experts from UCLA's Jonsson Comprehensive Cancer Center, led by Dr...
Avastin Can Lengthen The Lives Of Advanced Cervical Cancer Patients
6/03/2013
The addition of targeted therapy Avastin (bevacizumab) with chemotherapy can significantly lengthen the lives of women with advanced cervical cancer by close to 30%, according to research presented at the 2013 American Society of Clinical Oncology Congress. The finding is an important discovery in the fight against cervical cancer - the most common cancer in women under the age of 35...
10 Years On Tamoxifen Halves Breast Cancer Recurrence Risk
6/03/2013
Survivors who take tamoxifen for ten years have half the risk of dying from estrogen receptor positive breast cancer, researchers from Cancer Research UK reported at the ASCO Annual Meeting in Chicago, Illinois, USA...
HER2 Abnormalities Found In Many Advanced Cancers
6/03/2013
We already know that an over-active HER2 growth factor gene features in breast and gastric cancers. Now a new study reports finding mutations and other abnormalities of the gene in 14 different advanced cancers...
Sorafenib (Nexavar) Delays Rare Thyroid Cancer By 5 Months
6/03/2013
Sorafenib (Nexavar) stops metastatic thyroid cancer tumor growth for nearly twice as long as a placebo, researchers from Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania announced as they reported on a randomized phase III trial at the ASCO Annual Meeting in Chicago, Illinois...
Further Tests To Determine The Efficacy Of The Drug Nivolumab For Lung Cancer
6/03/2013
A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's on the market, according research that scientists at Fox Chase Cancer Center presented at the 49th Annual Meeting of the American Society of Clinical Oncology...
Discovery Of Possible Key To Cause Of Cushing Disease
6/03/2013
Cushing disease is a life-threatening disorder most commonly triggered by tumors, often benign, in the pituitary glands, resulting in excess production of adrenocorticotrophic hormone (ACTH)...
Many Solid Tumors Carry Genetic Changes Targeted By Existing Compounds
6/03/2013
Nearly two-thirds of solid tumors carry at least one mutation that may be targeted, or medicated, by an existing compound, according to new findings from researchers Fox Chase Cancer Center that will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology on June 3...
Seeking A Less Toxic Radiation Treatment For HPV-Positive Oropharynx Cancer
6/03/2013
Researchers from Fox Chase Cancer Center and other institutions have completed a phase II clinical trial that may help identify those patients with HPV-positive oropharyngeal cancer who do not require the full radiation dose given in a standard regimen of Intensity-Modulated Radiation Therapy (IMRT)...